Real World Clinical Outcomes in Cisgender Female Patients Who Start on Long Acting Cabotegravir for PrEP: An Observational, Multisite Prospective 2 Year Study in the Southern U.S.
Status: Recruiting
Location: See all (3) locations...
Intervention Type: Drug
Study Type: Observational
SUMMARY
Oral PrEP regimens (FTC/TDF have been the mainstay of HIV prevention however patients now have more options for HIV prevention. In addition to oral PrEP regimens, the FDA approved the use of long acting Cabotegravir (CAB-LA) as the first long-acting medication for HIV prevention. This study will evaluate real world clinical outcomes of cisgender female patients who start CAB-LA for PrEP.
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
View:
• Cisgender females, ages 18 years and older
• Negative HIV test at baseline
• Negative Pregnancy test at baseline
• Weigh at least 35 kilograms
• Already Prescribed CAB-LA (Apretude)
Locations
United States
Florida
Midway Specialty Care Center
RECRUITING
Orlando
Midway Specialty Care Center
NOT_YET_RECRUITING
Temple Terrace
Midway Specialty Care Center
RECRUITING
West Palm Beach
Time Frame
Start Date: 2024-01-02
Estimated Completion Date: 2027-03-31
Participants
Target number of participants: 100
Treatments
Cisgender Females
Related Therapeutic Areas
Sponsors
Leads: Midway Specialty Care Center